

**St John's DermAcademy Podcasts**  
**by Dr Sarah Drummond**

**Episode 17: Eczema Therapeutics - Part 2**



**Professor Catherine Smith**

**Professor of Dermatology and Therapeutics**

St John's Institute of Dermatology

Guy's and St Thomas' NHS Foundation Trust and  
King's College London



**Dr Andrew Pink**

**Consultant Dermatologist and Director of Adult  
Clinical Trials Unit**

St John's Institute of Dermatology

Guy's and St. Thomas' NHS Foundation Trust

**In this episode we discuss...**

- The use of JAK inhibitors licensed for use in managing eczema including their mechanism of action, monitoring requirements and potential side effects.
- Newer agents currently under investigation.
- The BEACON trial

**References and further reading:**

- NICE guidance – Abrocitinib, tralokinumab or Upadacitinib for treating moderate to severe atopic dermatitis: <https://www.nice.org.uk/guidance/ta814>
- NICE guidance – Baricitinib for treating moderate to severe atopic dermatitis: <https://www.nice.org.uk/guidance/ta681>
- MHRA guidance regarding JAK inhibitors <https://www.gov.uk/drug-safety-update/janus-kinase-jak-inhibitors-new-measures-to-reduce-risks-of-major-cardiovascular-events-malignancy-venous-thromboembolism-serious-infections-and-increased-mortality>

- Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the ORAL surveillance trial <https://ard.bmj.com/content/82/3/331>
- Green Book guidance for Shingrix vaccine: [https://assets.publishing.service.gov.uk/media/6603fedef9ab41001aeea371/Shingles\\_Green\\_Book\\_chapter\\_28a\\_20240315.pdf](https://assets.publishing.service.gov.uk/media/6603fedef9ab41001aeea371/Shingles_Green_Book_chapter_28a_20240315.pdf)
- BEACON trial information: <https://www.beacontrial.org/>